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M A J O R A R T I C L E
Molecular Epidemiology of Infant Botulism in
California and Elsewhere, 1976–2010
Haydee A. Dabritz,1,a Karen K. Hill,2 Jason R. Barash,1 Lawrence O. Ticknor,3 Charles H. Helma,2 Nir Dover,1
Jessica R. Payne,1 and Stephen S. Arnon1
1Infant Botulism Treatment and Prevention Program, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of
Public Health, Richmond, California; 2Bioscience Division, and 3Computing, Computational and Statistical Sciences Division, Los Alamos National
Laboratory, Los Alamos, New Mexico
Background. Infant botulism (IB), first identified in California in 1976, results from Clostridium botulinum
spores that germinate, multiply, and produce botulinum neurotoxin (BoNT) in the immature intestine. From
1976 to 2010 we created an archive of 1090 BoNT-producing isolates consisting of 1012 IB patient (10 outpatient,
985 hospitalized, 17 sudden death), 25 food, 18 dust/soils, and 35 other strains.
Methods. The mouse neutralization assay determined isolate toxin type (56% BoNT/A, 32% BoNT/B). Ampli-
fied fragment-length polymorphism (AFLP) analysis of the isolates was combined with epidemiologic information.
Results. The AFLP dendrogram, the largest to date, contained 154 clades; 52% of isolates clustered in just 2
clades, 1 BoNT/A (n = 418) and 1 BoNT/B (n = 145). These clades constituted an endemic C. botulinum population
that produced the entire clinical spectrum of IB. Isolates from the patient’s home environment (dust/soil, honey)
usually located to the same AFLP clade as the patient’s isolate, thereby identifying the likely source of infective spores.
C. botulinum A(B) strains were identified in California for the first time.
Conclusions. Combining molecular methods and epidemiological data created an effective tool that yielded
novel insights into the genetic diversity of C. botulinum and the clinical spectrum, occurrence, and distribution
of IB in California.
Keywords. botulinum toxin; clinical spectrum; Clostridium baratii; Clostridium botulinum; Clostridium
butyricum; honey; infant botulism; molecular epidemiology; sudden infant death.
Infant botulism (IB) results when swallowed spores of
Clostridium botulinum (or rarely, neurotoxigenic C. bu-
tyricum or C. baratii) germinate, multiply, and produce
botulinum neurotoxin (BoNT) in the large intestine.
BoNT, the most poisonous substance known, causes
constipation, bulbar palsies, and flaccid paralysis in in-
fants by blocking acetylcholine release at the neuromus-
cular junction [1]. Approximately 20–50 IB cases occur
annually in California, more than in any other state.
Since initial identification of IB in California in 1976
[2–4], the California Department of Public Health In-
fant Botulism Treatment and Prevention Program has
archived patient epidemiological information and
C. botulinum strains isolated from patients’ feces and
their home environments.
Seven botulinum toxin types (A–G) are currently
known (an eighth was recently recognized [5, 6]); bont
gene sequencing has identified toxin subtypes or vari-
ants [7–10] (eg, A1, A2). Although most isolates pro-
duce a single toxin type, dual-toxin-producing strains
(Ab, Af, Ba, Bf, Bh) [5, 11–14] and type A strains with
an unexpressed bont/B gene, denoted A(B), exist [15–
17]. Neurotoxigenic C. butyricum produces BoNT/E,
while neurotoxigenic C. baratii produces BoNT/F
[18, 19].
Because the BoNT gene (bont) cluster is associated
with mobile genetic elements, the BoNT-producing
clostridia exhibit substantial genomic diversity, identifi-
able by various molecular techniques (reviewed in [10]).
We utilized amplified fragment-length polymorphism
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(AFLP) analysis for this study because of its robustness and
suitability for examining large collections of C. botulinum iso-
lates [7, 20, 21], together with real-time polymerase chain reac-
tion (RT-PCR) to identify bont subtypes, and combined the
molecular results with epidemiologic and clinical information.
This combination provided novel and unexpected insights into
both the bacterium and the occurrence of IB in California and
other parts of North America in the past 35 years.
METHODS
Case Definition, Case Identification, and Collection of
Epidemiologic Data
An IB case was defined as an infant with symptoms consistent
with the known paralyzing action of BoNT, including sudden
death, in which BoNT orC. botulinum was identified in intestinal
contents or feces. Cases outside of California were identified
through distribution of Human Botulism Immune Globulin In-
travenous (BIG-IV; BabyBIG [1]) and had C. botulinum freshly
isolated from a second fecal specimen or were identified through
the Centers for Disease Control and Prevention (CDC) national
surveillance reports (http://www.cdc.gov/nationalsurveillance/
botulism-surveillance.html). Cases were assigned to the state
and county in which the infant lived for the 2 weeks immediately
before onset (defined as the date on which the parent first
contacted a medical provider about the symptoms of the illness).
The incidence calculations included all US IB cases from 1976
to 2010 and live-births in California by county and nationwide
by state, available from the California Department of Public
Health (CDPH) at http://www.cdph.ca.gov/data/statistics/Pages/
StatewideBirthStatisticalDataTables.aspx (accessed November
21, 2011) and from the National Center for Health Statistics, Hy-
attsville, MD, at http://www.cdc.gov/nchs/births.htm (accessed
December 8, 2011), respectively. Epidemiological data for all Cal-
ifornia and BIG-IV-treated patients elsewhere were obtained by
home visit and/or telephone interview.
Culture and DNA Isolation
Clostridium botulinum was originally isolated from patient and
environmental specimens using standard methods [22], frozen
at −70°C, and then freshly cultured to create cell pellets for
DNA isolation (see online Supplementary Data) that followed
the protocol for DNA extraction from Gram-positive bacteria
using the Qiagen DNeasy Blood and Tissue Kit.
AFLP Analysis
For AFLP analysis, DNA preparations were digested with 2 re-
striction enzymes selected for A/T-rich genomes, linkers were
ligated to the resulting fragments, and a series of PCR amplifica-
tions were performed as previously described [7]. Forty DNA
fragment sizes were used to create a genetic fingerprint represent-
ing each isolate [23]. Clustering analysis of the fragment sizes for
the 1091 isolates created a dendrogram with 154 clades. (The non-
toxigenic C. sporogenes ATCC 11437 isolate was part of the col-
lection.) Differences of >0.20 genetic distance units, the error
inherent to the method, differentiated the clades from each
other. (See online Supplementary Data for details.)
Toxin Gene Characterization by RT-PCR
Six hundred thirty-five type A and type B isolates, 58% of the
collection, were characterized by RT-PCR to determine the sub-
type and presence of an unexpressed (“silent”) bont/B gene (see
online Supplementary Data for primers, probes, and conditions
used).
Spatial Analysis
Latitude and longitude coordinates were assigned to the pa-
tient’s residence address at onset of illness, with ZIP code or
city centroid coordinates assigned for nonmatching or missing
addresses. For clades with ≥10 isolates, SaTScan (http://www.
satscan.org) with a case-control model was used to search for
geographic or geographic-temporal clusters within that clade
by comparing its IB patient isolates to those of all other Califor-
nia IB patients [24]. Environmental, food, and sudden-death
case isolates were excluded from this analysis. Possible geo-
graphic-temporal clusters were sought in circular geographic
areas of radius ≤125 km and maximum time windows of ≤5
years (see online Supplementary Data for details).
RESULTS
Infant Botulism Occurrence in California and Elsewhere
From 1976 to 2010, 2803 IB cases were reported in the United
States; 1093 (39%) occurred in California. Table 1 lists the ori-
gins of the 1091 isolates studied. These 1091 isolates included
1012 IB patient isolates: 948 California, 55 other US states,
and 9 other countries. These 1012 IB patients included the en-
tire clinical spectrum of IB (ie, 10 outpatient, 985 hospitalized,
and 17 sudden-death cases). An additional 79 patient-associated
environmental isolates and reference strains were also analyzed.
By the mouse neutralization assay, the 1090 neurotoxigenic iso-
lates consisted of 609 (56%) BoNT/A; 345 (32%) BoNT/B; 22
(2%) bivalent BoNT/Af, /Ba, or /Bf; 11 (1%) BoNT/E; 9 (1%)
BoNT/F; and 8 (1%) BoNT/C, /D or /G. Eighty-six (8%) strains
were A(B) (Table 1).
The distribution of IB cases in California reflected the under-
lying population, with IB cases generally occurring in or near
large population centers in the Los Angeles basin, San Francisco
Bay area, and metropolitan San Diego (Figure 1A–D). However,
cases also occurred in less populated rural areas. More than half
of California IB cases were caused by BoNT/A strains and ap-
proximately one-third by BoNT/B strains. In comparison, biva-
lent and C. baratii BoNT/F strains were rare. IB incidence from
1976 to 2010 was 6.2/100 000 live-births, almost 3-fold higher
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than the nationwide incidence of 2.1/100 000 live-births in the
same interval. The annual ratio of BoNT/A to BoNT/B cases in
California over the 35-year study was 1.7 (range, 0.7–8.5).
AFLP Analysis and bont RT-PCR Characterization
The AFLP dendrogram differentiated the 1091 clostridial iso-
lates into 154 clades, 64 with multiple isolates and 90 with only
a single isolate (Figure 2; Supplementary Data Appendix I).
A striking feature of the dendrogram was its 2 largest clades,
1 containing 418 BoNT/A isolates (n = 387 California IB
patients, Figure 1B) and the other containing 145 BoNT/B iso-
lates (n = 141 California IB patients, Figure 1D). Hence, these 2
clades contained more than half (563; 52%) of all the isolates in
the collection and represented the 2 predominant genotypes of
C. botulinum that have caused IB in California for the past 35
years. The other 528 isolates of the collection located to the 152
other clades within the dendrogram.
The bont gene RT-PCR characterization identified subtypes/
variants bont/A1, /A2, /A4, and bont/B1, /B2, /B3, /B4, /B5, and
silent B (Figure 2). The Loch Maree BoNT/A3 strain, the only
BoNT/A3 isolate in the collection, was included for reference
purposes [25, 26]. The 86 A(B) isolates containing the unex-
pressed bont/(B) gene located to 14 clades; 67 isolates were
from California IB patients (Figure 3A). Also, a large number
of bivalent BoNT/Ba (n = 17), and /Bf (n = 3) and C. baratii
type F (n = 2) isolates were obtained from infant botulism
cases that occurred in different years and geographic locations
in California (Figure 3C).
Isolates From Outpatient and Sudden-Death Cases
The clinical spectrum of IB includes outpatient, hospitalized,
and fulminant (ie, sudden-death) cases [27, 28]. Ten IB outpa-
tient isolates located to 5 clades: 4 to the largest BoNT/A clade,
3 to a closely related BoNT/A clade, 1 to the largest BoNT/B
clade, 1 to the largest A(B) clade, and 1 to a small BoNT/A
clade. Twelve of the 17 sudden-death cases located to the largest
BoNT/A clade and 1 to the largest BoNT/B clade (Figure 2; Sup-
plementary Data Appendix I). Hence, both the largest BoNT/A
and the largest BoNT/B clades contained C. botulinum isolates
indistinguishable by AFLP analysis that produced the entire
clinical spectrum of infant botulism.
Clades Associated With Honey Consumption
The AFLP analysis produced 2 clades that contained isolates
both from honeys and from IB patients fed those honeys before
onset of illness. The first clade contained 5 BoNT/A2 isolates
from 4 patients (1982, 1995, 1997, 2001) and from 1 commercial
honey consumed by the 1982 patient. The honeys fed to the other
3 patients were not available for testing. The second clade associ-
ated with honey consumption contained 18 patient and 8 honey
type B isolates from 1983 to 1988 (Table 2). All 26 isolates were
subtyped and determined to be bont/B5. Fourteen (78%) of the 18
patients had been fed honey in the month before onset of illness,
and 7 of the 8 honey isolates in this clade were from honeys con-
sumed by 6 of the patients. One patient without a history of honey
consumption lived in the honey-producing area.
Clades Associated With Dust and Soils Collected at Patients’
Homes
Clostridium botulinum was isolated from 14 environmental
samples from the homes of 8 IB patients (Table 1, footnote
b), of which 11 located to the same clade as the patient’s isolate.
The co-location of patient and environmental isolate(s) in the
same clade included: 1 vacuum cleaner dust and 2 soil isolates
from the home of 2 sibling type A patients in an Alameda
County city; 1 vacuum cleaner dust and 2 soil isolates from
Table 1. Source and Geographic Origin of Clostridial Isolates in the AFLP-Based Dendrogram (n = 1091)
Source California
United States
(Outside California)
International
(Outside United States) Unknown Total
Infant botulisma 948 55 9 . . . 1012
Honey 13 . . . . . . . . . 13
Other foods 2 7 3 . . . 12
Environmental 14b 2 2 . . . 18
Foodborne botulism 2 . . . . . . . . . 2
Wound botulism 12 3 . . . . . . 15
Intestinal toxemia 1 1 2 . . . 4
Reference strainsc . . . 5 6 4 15
Total 992 73 22 4 1091
Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin.
a Includes 10 outpatient and 17 sudden-death cases.
b n = 11 soil, n = 2 vacuum cleaner dust, and n = 1 ceiling fan dust; isolates collected from California IB patient homes.
c Includes reference strain C. sporogenes ATCC11 437. Note that the bottom 4 rows of the table consist of 35 BoNT-producing isolates and 1 nontoxigenic C.
sporogenes strain.
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Figure 1. Infant botulism cases caused by C. botulinum types A and B in California, 1976–2010. A, All BoNT/A IB patient isolates (n = 560), excluding
A(B) isolates. B, Isolates in the largest AFLP BoNT/A clade, which contained a type A Hall strain, 383 California hospitalized IB cases, 4 outpatient cases,
and 12 sudden-death cases (not included on map). Note that cases occurred in all 35 years of the study period. A geographic but not temporal cluster of
radius 35 km was detected near Escondido (San Diego County). C, All BoNT/B IB patient isolates (n = 282). D, The largest AFLP BoNT/B clade (n = 141). Note
that cases occurred in all years of the study period except for 1979, 1992, 1993, and 2008. One geographic but not temporal cluster was identified in the Los
Angeles area near Anaheim (radius 39 km). Geographic-temporal clustering was determined using the Kulldorff spatial-scan statistic with a case-control
model [24]. Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin; IB, infant botulism.
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Figure 2. Schematic diagram of the AFLP dendrogram of 1091 clostridial isolates. Note that more than half the isolates (52%) located to just 2 large
clades, 1 of toxin type A and the other of toxin type B. Note also the wide separation of the 2 major A(B)-containing clades, the bivalent (BoNT/Ba- and /Bf-
containing) clades and other BoNT/A- and /B-containing clades. Dendrogram constructed using 40 DNA fragments and a cluster algorithm with the Jaccard
distance measure [23]. The full Figure 2 in pdf format may be found in Supplementary Data Appendix I; when the isolates in it are displayed in an 8-point
font, the figure measures approximately 4.5 m in length. Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin.
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Figure 3. Occurrence and distribution of A(B), bivalent (Ba, Bf ) and rare strains of C. botulinum. A, All A(B) California IB patient isolates (n = 66) located to
6 multimember and 5 singleton clades. One California 3-year-old intestinal toxemia patient isolate and 2 WB isolates not depicted. B, The second-largest
A(B) clade (n = 23) included 20 California patients and contained a geographic-temporal cluster of 3 patients near Bakersfield. C, BoNT/Ba (n = 17), BoNT/Bf
(n = 3) and C. baratii type F (n = 2) California IB patient isolates. D, Clade of 12 BoNT/B, /Ba and /Bf patient isolates. Geographic-temporal clusters deter-
mined using the Kulldorff spatial-scan statistic [24]. Abbreviations: BoNT, botulinum neurotoxin; IB, infant botulism; WB, wound botulism.
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the Sierra Nevada foothills home of a Madera County type A
patient; type A soil isolates from the homes of type A patients
in Ontario, California, and Reno, Nevada; and 1 type B soil iso-
late and 1 ceiling fan dust type B isolate from the home of 2 type
B twin patients in Stanislaus County. The 3 exceptions to the
clade co-location of patient and environmental isolates consist-
ed of a type A soil isolate and a type B soil isolate from the Al-
ameda County home of the 2 type A sibling patients and 2 type
A soil isolates from the homes of 2 Yolo County type A patients.
The Largest BoNT/A Clade
This clade contained 418 isolates from 399 California IB pa-
tients (Table 2, #1; Figure 1B), 1 IB patient from Mexico, 4 IB
patients from neighboring western states (Idaho, Nevada, Utah,
Washington), 5 wound botulism (WB) patients (n = 4 Califor-
nia, n = 1 Utah), 3 honeys, 2 food items (carrots, cow’s liver),
3 soil isolates associated with patients (n = 2 California, n = 1
Nevada), and a Hall strain. All 12 isolates subtyped were
bont/A1. Notably, no isolates in this clade were from states
east of the Rocky Mountains.
Geospatial analysis of the 387 California IB patient isolates
(excluding the 12 sudden-death cases) in this clade identified
a geographic cluster centered near Escondido (San Diego Coun-
ty) that contained 27 IB cases (radius approximately 35 km;
P = .005) (Figure 1B). Two other closely related BoNT/A clades
(Table 2, #2–3) also contained geographic clusters: 1 clade
(n = 12) contained a cluster of 7 isolates centered near Rialto
(San Bernardino County) (radius approximately 15 km;
P < .001), and the other clade (n = 70) contained a cluster of
48 isolates (76% of the clade’s IB cases) centered near Napa,
north of San Francisco Bay (radius approximately 124 km;
P < .001).
Table 2. Descriptive Features of the Largest Clades (≥10 Isolates) Identified by AFLP Analysis
AFLP Clade in Figure 2a
Figure/Panel
Where
Mapped
Years
Isolated
Number and Source of Isolates
CA IB
Isolates
IB Isolates
From Outside
CA
Environ-
mentalb
Food/
Honeyb WB
Reference
Strainsc
1. Largest BoNT/A 1/B 1976–2010 399d 5 3 3 5 3
2. Southern California A closely
related to above largest BoNT/A
N/A 1987–2007 12 . . . . . . . . . . . . . . .
3. Northern California A closely
related to above largest BoNT/A
N/A 1977–2010 66e 1 3 . . . . . . . . .
4. Northern California BoNT/A 4/A 1977–2010 23 . . . 5 . . . . . . . . .
5. Largest A(B) N/A 1977–2010 31 9 . . . . . . 2 1
6. Central Valley A(B) 3/B 1979–2010 20 3 . . . . . . . . . . . .
7. Largest BoNT/B 1/D 1976–2010 142f 1 2 . . . . . . . . .
8. Primarily Southern California
BoNT/B closely related to the
above largest BoNT/B clade
N/A 1980–2001 12 . . . . . . . . . . . . . . .
9. East San Francisco Bay area
BoNT/B
4/B 1978–2009 10 . . . 1 . . . . . . . . .
10. Primarily 1992–1994 BoNT/B 4/C 1992–1999 30g . . . . . . . . . . . . . . .
11. Southern California BoNT/B N/A 1983–1988 18 . . . . . . 8h . . . . . .
12. Primarily 2000s BoNT/B 4/D 2008–2009i 10 . . . . . . . . . 1 . . .
13. BoNT/B, BoNT/Ba, BoNT/Bf 3/D 1978–2004 12 . . . . . . . . . . . . . . .
14. Primarily Mid-Atlantic BoNT/B N/A 2005–2010 1 10 . . . . . . . . . . . .
Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin; CA, California; IB, infant botulism; N/A, not applicable; WB, wound
botulism.
a Geographical coordinates of patient isolate clusters within these clades may be found in Table 3.
b Isolates associated with CA IB patients.
c Reference strains that locate to the largest BoNT/A clade: Hall strain; 62A (Nevada cow liver 1921 [29]); California carrot 2006 [30]. Reference strains that located to
the largest A(B) clade: NCTC 2916 Colorado yellow corn 1929 [16].
d Includes 4 outpatient (shown) and 12 sudden-death cases (not shown) in Figure 1B.
e Includes 3 outpatient and 3 sudden-death cases.
f Includes 1 sudden-death case not shown in Figure 1D.
g All but 1 case occurred in 1992–1994.
h Includes 1 isolate from a honey producer in Tulare County.
i Nine of 10 IB cases occurred in 2008–2009. In 1986, the tenth case traveled from San Diego County to the San Francisco Bay area through the Los Angeles basin
(center of the 2008–2009 geographic cluster) within 2 weeks of onset of illness. The WB case (not shown in Figure 4D) occurred in 1999 in Santa Clara County.
Infant Botulism—Molecular Epidemiology • JID • 7
 
The Largest BoNT/B Clade
This clade (Table 2, #7; Figure 1D) contained 145 isolates, 142
of which were from California IB patients, including 1 outpa-
tient and 1 sudden-death case. The single strain in the clade
not from California was isolated in 1979 from the first-recog-
nized IB patient in the Czech Republic [31]. All 6 isolates sub-
typed were bont/B1. This clade contained a geographic cluster
in Southern California centered near Anaheim (Los Angeles
County) (radius approximately 39 km; P = .001) that contained
71 (50%) of the clade’s California IB patients.
A(B) Strain Clades
The analysis identified 86 C. botulinum A(B) isolates (66 from
California IB patients and 14 from IB patients in Alaska, Arkan-
sas, Colorado, Georgia, Illinois, Nevada, New Mexico, Oklaho-
ma, Texas, Washington, and Wyoming). Such A(B) strains were
not previously known to exist in California (Table 2, #6; Fig-
ure 3A). The A(B) isolates located to 14 clades (7 multimember
clades and 7 singleton clades); 5 clades contained non-California
A(B) strains, and 2 contained both A(B) and type B strains.
A(B) strains were isolated in California in all years of the
study period except 1976, 1978, 1983, and 1995 (Figure 3A).
The largest A(B) clade (n = 43) contained isolates from 31 Cal-
ifornia IB patients, 8 other US IB patients, 1 Canada IB patient,
2 California WB patients and the National Collection of Type
Cultures reference strain NCTC 2916 (Table 2, #5). This clade
had no geographic clusters in California, whereas the second-
largest A(B) clade (Table 2, #6) contained a geographic-tempo-
ral cluster from 2006 to 2009 centered in California’s Central
Valley near Bakersfield (Kern County) (radius approximately
8 km; P = .047) that contained 3 IB cases (Figure 3B).
Bivalent (Ba, Bf ) Clades
The molecular analysis identified 17 bivalent B5a4 isolates that
located to 5 clades and 4 B5f isolates, 3 from California and 1
from Texas, that located to 3 clades. The largest of the bivalent
clades (Table 2, #13) notably contained several B5 and B5a4
isolates and 1 B5f isolate (Figure 3D). A single unique strain
that contained a bont/A5 gene and a partial bont/B gene [the
bont/A5(B3′) gene arrangement [9]] that was isolated from a
San Diego County IB patient located to a singleton clade.
Mid-Atlantic US Type B Clades
Two clades of BoNT/B patient isolates mapped mainly to cer-
tain areas in the eastern Mid-Atlantic United States. The first
clade (n = 8) included the 1939 Tennessee BoNT/B1 Okra ref-
erence strain [32], 3 patients from Maryland, and 1 patient each
from New Jersey, Pennsylvania, Alabama, and California. The
California IB patient was born prematurely and had not been
discharged from her birth hospitalization before onset of illness.
However, some of the specialty formulas fed to her were pro-
duced in the Mid-Atlantic region; although these formulas test-
ed negative for C. botulinum, 1 contained C. sporogenes. The
second Mid-Atlantic BoNT/B clade (Table 2, #14) contained
11 bont/B1 isolates: 8 IB patients from either New Jersey,
New York, or Pennsylvania; 1 patient from Colorado; and 2
patients from California and Oregon who had traveled to
New York City and Pennsylvania, respectively, in the month be-
fore onset of illness. Geographical clustering in these clades
could not be evaluated because the reference set of East Coast
patient isolates was too small.
Other Noteworthy California Clades
Five additional California clades demonstrated either geograph-
ic or geographic-temporal clustering. A BoNT/A clade with 23
California IB patient and 5 environmental isolates (Table 2, #4;
Figure 4A) had a geographic-temporal cluster of 7 patients from
2005 to 2008 centered northeast of Sacramento (radius approx-
imately 101 km; P = .003).
The second clade, BoNT/B with 10 IB patient and 1 soil iso-
late (Table 2, #9; Figure 4B), had a geographical cluster of 9 pa-
tient isolates that centered east of San Francisco Bay (radius of
approximately 69 km; P = .002). The third clade, BoNT/B with
30 California IB patient isolates, contained a geographic-tempo-
ral cluster from 1992 to 1994 in southern California with 18 pa-
tient isolates centered in the San Fernando Valley (Los Angeles
County) (radius approximately 97 km; P < .001) (Table 2, #10;
Figure 4C). The fourth clade of 12 BoNT/B California patients
Table 3. Geographical Coordinates of Patient Isolate Clusters
AFLP Clade in Figure 2
Figure/Panel
Where
Mapped
Cluster Center,
Lat/Long
1. Largest BoNT/A 1/B 33.12, −117.06
2. Southern California A closely
related to above largest BoNT/A
N/A 34.11, −117.38
3. Northern California A closely
related to above largest BoNT/A
N/A 38.31, −122.32
4. Northern California BoNT/A 4/A 38.63, −121.22
5. Largest A(B) N/A None
6. Central Valley A(B) 3/B 35.32, −119.09
7. Largest BoNT/B 1/D 33.83, −117.98
8. Primarily Southern California
BoNT/B closely related to the
largest BoNT/B clade
N/A 34.16, −118.13
9. East San Francisco Bay area
BoNT/B
4/B 37.73, −121.44
10. Primarily 1992–1994 BoNT/B 4/C 34.29, −188.49
11. Southern California BoNT/B N/A 34.06, −118.43
12. Primarily 2000s BoNT/B 4/D 34.43, −118.47
13. BoNT/B, BoNT/Ba, BoNT/Bf 3/D None
14. Primarily Mid-Atlantic BoNT/B N/A ND
Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT,
botulinum neurotoxin; Lat/Long, latitude/longitude; N/A, not applicable; ND,
not determined.
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Figure 4. Geographic and geographic-temporal clusters of California IB cases between 1976 and 2010. A, BoNT/A clade of 23 patient isolates with a
geographic-temporal cluster centered near Sacramento. This clade also contained 1 vacuum cleaner dust and 2 soil isolates (not shown). B, BoNT/B clade of
10 California patient isolates that clustered in the east San Francisco Bay area. The sole outlier patient lived in a central coastal county, had not traveled,
and had been fed nonsterile solid foods. This BoNT/B clade also contained 1 soil isolate (not shown) from a patient home in an eastern San Francisco Bay
city. C, BoNT/B clade of 30 California patient isolates with a geographic-temporal cluster that occurred in southern California, 1992–1994. Note the absence
of this particular C. botulinum type B strain in California patients before 1992 and after 1999, with 97% of the cases in the clade having occurred in the 4
years 1992–1994. D, BoNT/B clade of 10 California IB patient isolates with a geographic-temporal cluster in southern California (1 WB patient from 1999
not shown). All IB cases occurred in 2008–2009 except for the 1986 case, who was driven through the Los Angeles basin (center of cluster) 2 weeks before
onset of illness when the family moved from San Diego County to the San Francisco Bay area. Geographic-temporal clusters were determined using the
Kulldorff spatial-scan statistic [24]. Abbreviations: BoNT, botulinum neurotoxin; IB, infant botulism; WB, wound botulism.
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that also clustered in southern California both temporally
(1980–1983) and geographically was centered near Pasadena
(radius approximately 30 km; P = .015) (Table 2, #8).
The fifth clade, BoNT/B with 10 IB and 1 WB patient isolates
(Table 2, #12; Figure 4D), contained a 2008–2009 geographic-
temporal cluster of 6 patient isolates centered in the Santa
Clarita Valley (Los Angeles County) (radius approximately
68 km; P < .001). Nine of 10 IB patients in this clade became
ill in 2008–2009; in 1986, the tenth patient became ill 2 weeks
after traveling through the Los Angeles basin (the center of the
cluster).
DISCUSSION
The Infant Botulism Treatment and Prevention Program
(IBTPP) collection of neurotoxigenic clostridial strains provid-
ed a unique opportunity to combine molecular and epidemio-
logical information to better understand IB in California.
Significant novel findings of this endeavor included: (1) the
identification of 2 large clades that contained endemic strains
that caused more than half of the BoNT/A and more than
one-third of the BoNT/B IB cases in California in the 35-year
study period; (2) the co-location of patient isolates from all 3
segments of the IB clinical spectrum (outpatient, hospitalized,
sudden death) to the same BoNT/A or BoNT/B clade; (3) the
identification of C. botulinum A(B) isolates in IB patients
from California and 11 other US states that would not have
been identified by the mouse neutralization assay; (4) the iden-
tification of rare strains isolated from 25 IB and 2 adult botulism
cases that include BoNT/B5a4 (n = 17), BoNT/Bf (n = 4), and C.
baratii BoNT/F (n = 6) isolates; (5) the recognition of clades
whose isolates share a common-source origin (eg, honey); (6)
the identification of clades whose isolates are restricted geo-
graphically to limited areas of California; and (7) the co-loca-
tion to the same clade of C. botulinum patient and associated
dust, soil, and honey isolates that could cause IB when swal-
lowed by susceptible infants. The extensive branching of the
dendrogram displays and emphasizes the different genetic back-
grounds of C. botulinum strains that express the same toxin
types.
Clostridium botulinum type A(B) isolates have been reported
from Alaska, Arizona, Colorado, Georgia, Illinois, Louisiana,
Nebraska, New Mexico, Pennsylvania, Puerto Rico, Wisconsin,
and West Virginia [29, 33–35]. In this study, A(B) isolates were
newly identified in IB patients from Arkansas, California, Neva-
da, Oklahoma, Texas, Washington, and Wyoming, further sug-
gesting that A(B) strains are widespread throughout the United
States. The molecular analysis and mouse neutralization assay
also identified 17 bivalent BoNT/B5a4 and 3 BoNT/Bf isolates
that caused IB in California. Recognition of BoNT/B5a4 strains
outside of California that cause IB has occurred infrequently;
only the 1976 Texas [36–38] and 1999 Texas and 2006 Nevada
patients reported in the CDC annual national botulism surveil-
lance summaries were previously known.
TheAFLPanalysis also identified clades that contained isolates
associated with honey exposure or that contained geographic-
temporal clustering. The 4 patients in the only bont/A2 clade
were fed honey; the clade also contained a bont/A2 isolate
from a honey consumed by 1 of the patients. The BoNT/A2
subtype had previously been isolated only from Argentinian
soils and from IB patients in Argentina [39], Italy [33], and
Japan who were fed honey [40], as well as from a Brazilian
honey [40] and from honey [41] fed to a New Jersey patient
that may have contained blended imported Argentinian
honey. Because honey may harbor C. botulinum spores, all
major public health, pediatric, and honey-producing institu-
tions have recommended that honey not be fed to infants [42].
Three clusters within California BoNT/B clades occurred in
limited time spans: 1 in 1992–1994 (Figure 4C), 1 in 2008–2009
(Figure 4D), and 1 in 1983–1985 (not shown). The latter oc-
curred in a clade of monovalent BoNT/B5 isolates associated
with honey exposure; interestingly, no monovalent BoNT/B5-
producing isolates have been identified in California since
1988. No common-source exposures to a food or environmental
source were identified for the temporal clusters in the 2 other
BoNT/B clades. Possible sources of exposure to C. botulinum
spores include nonsterile infant foods (eg, powdered infant
formulas, dry cereals, herbal teas [43–45]), and anthropomor-
phic activities or weather phenomena that disrupt surface soil
[46, 47].
Geographical localization of isolates in some clades (Fig-
ures 1, 3, and 4) suggests that local soil and/or climatic conditions
may contribute to multiplication and subsequent dissemination
of C. botulinum spores. Notably, isolates from several patients
and their home environments (dust/soil, honey) located to
the same clade. Soil surveys in Argentina [48] and the United
States [49] have reported differing prevalences and BoNT
types in different geographic regions. In the United States,
BoNT/A strains predominate in soils west of the Mississippi
River, while BoNT/B strains predominate in soils east of the
Mississippi River; this regionalization matches the nationwide
distribution of IB patient toxin types [22]. Our geographic-
temporal analyses found that IB isolates from certain clades
concentrated in specific geographical areas; for example, a
BoNT/A clade northeast of Sacramento (Figure 4A), a BoNT/B
clade in the San Francisco Bay area (Figure 4B), and a BoNT/B
clade in the Santa Clarita Valley (Figure 4D). Two clades of
BoNT/B isolates from patients who resided primarily in the
Mid-Atlantic United States or had recently traveled there were
also identified. These examples suggest that IB may be acquired
from the local environment or while traveling in endemic areas.
In conclusion, the molecular analyses provided new and use-
ful information for elucidating epidemiological relationships
and for differentiating C. botulinum isolates. The study resulted
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in an AFLP dendrogram of 1091 isolates that displays the genet-
ic and epidemiological complexity of neurotoxigenic clostridia
(Figure 2 and Supplementary Data Appendix I). Importantly,
the geographical clustering of isolates was identified by use of
patient epidemiological information. The combination of mo-
lecular methods and epidemiological data created an effective
tool that yielded novel insights into the genetic diversity of C.
botulinum and the clinical spectrum, occurrence, and distribu-
tion of IB in California.
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